2-iodo-4-octylaniline | 876290-12-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-iodo-4-octylaniline
• CAS: 876290-12-9
• 化学式: C₁₄H₂₂IN
• 分子量: 331.24
• InChiKey: YQBWGNHKJZMDLX-UHFFFAOYSA-N

物化性质

• 沸点：
  371.0±35.0 °C(Predicted)
• 密度：
  1.348±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-iodo-4-octylaniline 在 盐酸 、 正丁基锂 、 氯化铵 、 溶剂黄146 、 sodium nitrite 作用下， 以 乙醚 、 正己烷 、 水 为溶剂， 反应 0.75h， 生成 [5-octyl-2-(pyrrolidin-1-yldiazenyl)-phenyl]boronic acid
  参考文献：
  名称：

  Dispirofluorene-indenofluorene (DSFIF):  Synthesis, Electrochemical, and Optical Properties of a Promising New Family of Luminescent Materials

  摘要：

  A series of new dispiro[fluorene-9 ',6,9 '',12-indeno[1,2b]fluorenes] (DSFIFs) that combine indenofluorene (IF) and spirobifluorene (SBF) architectural specificities have been prepared. Their anodic oxidations lead to the formation of nonsoluble transparent polymers. The photophysical and electrochemical properties of these new molecules have been evaluated for further blue OLED applications.

  DOI：

  10.1021/ol0526064
• 作为产物：
  描述：

  4-辛基苯胺 在 双氧水 、 碘 作用下， 以 甲醇 为溶剂， 以86%的产率得到2-iodo-4-octylaniline
  参考文献：
  名称：

  [EN] ORGANIC COMPOUNDS
  [FR] COMPOSÉS ORGANIQUES

  摘要：

  揭示了新型苯并呋喃衍生物。这些衍生物具有S1P1受体活性和/或疾病修饰活性，并可用于治疗与动物和/或人类的免疫、血管和神经系统相关的疾病或症状。

  公开号：

  WO2014063199A1

文献信息

• [EN] S1P RECEPTORS MODULATORS AND THEIR USE THEREOF<br/>[FR] MODULATEURS DES RÉCEPTEURS S1P ET LEUR UTILISATION
  申请人：AKAAL PHARMA PTY LTD

  公开号：WO2010043000A1

  公开（公告）日：2010-04-22

  The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

  这项发明涉及具有S1P受体调节活性的新化合物。此外，该发明涉及包括本发明中至少一种化合物的药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，例如自身免疫反应。该发明的另一个方面涉及使用包括本发明中至少一种化合物的药物制造药物，用于治疗由不当的S1P受体调节活性或表达引起或相关的疾病和/或病况，如自身免疫反应。
• Dispirofluorene–Indenofluorene Derivatives as New Building Blocks for Blue Organic Electroluminescent Devices and Electroactive Polymers
  作者：Cyril Poriel、Jing-Jing Liang、Joëlle Rault-Berthelot、Frédéric Barrière、Nicolas Cocherel、Alexandra M. Z. Slawin、David Horhant、Morgane Virboul、Gilles Alcaraz、Nathalie Audebrand、Laurence Vignau、Nolwenn Huby、Guillaume Wantz、Lionel Hirsch

  DOI：10.1002/chem.200701036

  日期：2007.12.17

  A series of new dispiro[fluorene-9',6,9'',12-indeno[1,2b]fluorenes] (DSF-IFs) has been synthesised. These new building blocks for blue-light-emitting devices and electroactive polymers combine indenofluorene (IF) and spirobifluorene (SBF) properties. We report here our synthetic investigations towards these new structures and their thermal, structural, photophysical and electrochemical properties.

  合成了一系列新的双螺并[芴-9'，6,9''，12-茚并[1,2b]芴]（DSF-IFs）。这些用于蓝光发射设备和电活性聚合物的新型构件结合了茚并芴（IF）和螺二芴（SBF）的特性。我们在这里报告了对这些新结构及其热，结构，光物理和电化学性质的综合研究。将这些特性与IF和SBF的特性进行了比较。我们还报告了导致不溶性透明三维聚合物形成的DSF-IFs的阳极氧化。已经研究了这些聚合物的结构和电化学行为。还报道了这些构件作为有机发光二极管（OLED）中新的蓝色发光材料的首次应用。
• S1P Receptors Modulators and Their Use Thereof
  申请人：Gill Gurmit S.

  公开号：US20110318388A1

  公开（公告）日：2011-12-29

  The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

  本发明涉及具有S1P受体调节活性的新化合物。此外，本发明涉及包括本发明中至少一种化合物的药物，用于治疗由不适当的S1P受体调节活性或表达引起或相关的疾病和/或病情，例如自身免疫反应。本发明的另一个方面涉及使用包括本发明中至少一种化合物的药物制造药物，用于治疗由不适当的S1P受体调节活性或表达引起或相关的疾病和/或病情，例如自身免疫反应。
• S1P receptors modulators and their use thereof
  申请人：Gill Gurmit S.

  公开号：US08592399B2

  公开（公告）日：2013-11-26

  The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

  这项发明涉及具有S1P受体调节活性的新化合物。此外，该发明涉及一种制药组合物，该组合物包括本发明中的至少一种化合物，用于治疗由或与不适当的S1P受体调节活性或表达有关的疾病和/或病情，例如自身免疫反应。该发明的另一个方面涉及使用包括本发明中的至少一种化合物的制药组合物制造药物，用于治疗由或与不适当的S1P受体调节活性或表达有关的疾病和/或病情，例如自身免疫反应。
• S1P RECEPTORS MODULATORS AND THEIR USE THEREOF
  申请人：AKAAL PHARMA PTY LTD.

  公开号：US20160038455A1

  公开（公告）日：2016-02-11

  The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, autoimmune response. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as autoimmune response.

  本发明涉及具有S1P受体调节活性的新化合物。此外，本发明涉及一种制药组合物，包括本发明中的至少一种化合物，用于治疗由于或与不当的S1P受体调节活性或表达有关的疾病和/或病症，例如自身免疫反应。本发明的另一个方面涉及使用包括本发明中的至少一种化合物的制药组合物制造用于治疗由于或与不当的S1P受体调节活性或表达有关的疾病和/或病症，例如自身免疫反应的药物。